Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
A:--
F: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
No matching data
Latest Views
Latest Views
Trending Topics
To quickly learn market dynamics and follow market focuses in 15 min.
In the world of mankind, there will not be a statement without any position, nor a remark without any purpose.
Inflation, exchange rates, and the economy shape the policy decisions of central banks; the attitudes and words of central bank officials also influence the actions of market traders.
Money makes the world go round and currency is a permanent commodity. The forex market is full of surprises and expectations.
Top Columnists
Enjoy exciting activities, right here at FastBull.
The latest breaking news and the global financial events.
I have 5 years of experience in financial analysis, especially in aspects of macro developments and medium and long-term trend judgment. My focus is maily on the developments of the Middle East, emerging markets, coal, wheat and other agricultural products.
BeingTrader chief Trading Coach & Speaker, 8+ years of experience in the forex market trading mainly XAUUSD, EUR/USD, GBP/USD, USD/JPY, and Crude Oil. A confident trader and analyst who aims to explore various opportunities and guide investors in the market. As an analyst I am looking to enhance the trader’s experience by supporting them with sufficient data and signals.
Latest Update
Risk Warning on Trading HK Stocks
Despite Hong Kong's robust legal and regulatory framework, its stock market still faces unique risks and challenges, such as currency fluctuations due to the Hong Kong dollar's peg to the US dollar and the impact of mainland China's policy changes and economic conditions on Hong Kong stocks.
HK Stock Trading Fees and Taxation
Trading costs in the Hong Kong stock market include transaction fees, stamp duty, settlement charges, and currency conversion fees for foreign investors. Additionally, taxes may apply based on local regulations.
HK Non-Essential Consumer Goods Industry
The Hong Kong stock market encompasses non-essential consumption sectors like automotive, education, tourism, catering, and apparel. Of the 643 listed companies, 35% are mainland Chinese, making up 65% of the total market capitalization. Thus, it's heavily influenced by the Chinese economy.
HK Real Estate Industry
In recent years, the real estate and construction sector's share in the Hong Kong stock index has notably decreased. Nevertheless, as of 2022, it retains around 10% market share, covering real estate development, construction engineering, investment, and property management.
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
View All
No data
Not Logged In
Log in to access more features
FastBull Membership
Not yet
Purchase
Log In
Sign Up
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
Tuesday, Merck & Co Inc released topline data from the HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who received prior EGFR tyrosine kinase inhibitor (TKI) treatment.
The study met its primary endpoint of progression-free survival (PFS), with patritumab deruxtecan demonstrating a statistically significant improvement versus platinum plus pemetrexed induction chemotherapy followed by pemetrexed maintenance chemotherapy.
Also Read: Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs.
Overall survival (OS) data were immature at the time of the analysis, and the trial will continue to assess OS, a secondary endpoint.
Patritumab deruxtecan is a specifically engineered potential first-in-class HER3-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo Ltd and being jointly developed by Daiichi Sankyo and Merck.
The safety profile seen in HERTHENA-Lung02 was consistent with that observed for patritumab deruxtecan in previous lung cancer clinical trials, with no new safety signals identified.
The majority of interstitial lung disease (ILD) events were low-grade (grades 1 and 2). Two grade 5 ILD events were observed.
Recently, Summit Therapeutics Inc. released data from the primary analysis of the Phase 3 HARMONi-2 trial of ivonescimab conducted in China, sponsored by collaboration partner Akeso, Inc.
The trial evaluated monotherapy ivonescimab against Merck’s Keytruda (pembrolizumab) in patients with locally advanced or metastatic non-small cell lung cancer whose tumors have positive PD-L1 expression.
Ivonescimab monotherapy demonstrated a statistically significant improvement in the trial’s primary endpoint, progression-free survival, compared to monotherapy pembrolizumab, achieving a hazard ratio of 0.51.
Price Action: MRK stock is up 0.39% at $118.42 during the premarket session at last check Tuesday.
Read Next:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
On Saturday, NuCana plc presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with Merck & Co Inc's Keytruda (pembrolizumab) for metastatic melanoma who were refractory to or had relapsed on prior PD-1 inhibitor therapy.
In this 12-patient cohort, most patients had received at least two prior lines of PD-1 inhibitor therapy.
Nine out of twelve (75%) achieved disease control, including two patients who achieved Partial Responses.
One of these patients, who had received two prior lines of PD-1 inhibitor-based therapy and had progressed on their latest treatment of ipilimumab plus nivolumab within two months, achieved a 55% reduction in tumor volume.
Seven of the 12 patients had a progression-free survival time of over five months.
Hugh Griffith, NuCana's Founder and CEO, said, "We are very excited to share these data on NUC-7738 in combination with pembrolizumab in PD-1 inhibitor refractory and resistant patients with melanoma. Outcomes in this patient population are very poor, with median progression-free survival of 2-3 months with the current standard of care, so we are very encouraged that the majority of patients who received this combination achieved a progression-free survival of more than five months."
In addition to achieving these encouraging efficacy signals, the combination of NUC-7738 and pembrolizumab had a favorable safety profile.
The company says NUC-7738 can sensitize PD-1-resistant tumors to rechallenge with PD-1 inhibitors due to its ability to target multiple aspects of the tumor microenvironment (TME) via the disruption of RNA polyadenylation and subsequent changes to gene expression in cancer cells.
Data from tumor biopsies obtained before and after NUC-7738-based treatment demonstrated increases in genes related to antigen presentation and T-cell activation.
In August, NuCana discontinued NuTide:323 study following a pre-planned initial analysis and recommendation from the NuTide:323 Study Steering Committee.
While there were prognostic imbalances favoring the control arm, the Steering Committee believed that the combination of NUC-3373 with leucovorin, irinotecan, and bevacizumab (NUFIRI+bev) was unlikely to achieve the study's primary objective of superior Progression-Free Survival compared to the control arm of 5-FU, leucovorin, irinotecan, and bevacizumab (FOLFIRI+bev) in the final analysis.
Price Action: NCNA stock is up 166.50% at $6.62 during the premarket session at last check Monday.
Read Next:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Considering buying GOOGL stock? Here’s what analysts think:
Read More:
Latest Ratings for GOOGL
Date | Firm | Action | From | To |
---|---|---|---|---|
Feb 2022 | MKM Partners | Maintains | Buy | |
Feb 2022 | Mizuho | Maintains | Buy | |
Feb 2022 | Piper Sandler | Maintains | Overweight |
View More Analyst Ratings for GOOGL
View the Latest Analyst Ratings
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The biotech space is incredibly exciting, given that companies are investing heavily to treat and prevent diseases. In fact, according to scientists, we might be in the golden age of biotechnology, making companies such as Summit Therapeutics top investment options right now. Several biotech players, including Summit Therapeutics, have strong drug candidates in clinical-stage trials on the cusp of approval.
Shares of Summit Therapeutics have soared over 1,120% in 2024, valuing the company at a market cap of $22.4 billion. Let’s see if it's too late to buy this breakout biotech stock right now.
An Overview of Summit Therapeutics
Miami-based Summit Therapeutics discovers, develops, and commercializes medicines to treat infectious diseases in the U.S. and Latin America. It conducts clinical programs focused on CDI or Clostridioides difficile infection.
Summit's lead product candidate is ridinilazole, an orally administered small-molecule antibiotic in Phase III clinical trials for the treatment of CDI.
Citi is Bullish on Summit Therapeutics Stock
Shares of Summit Therapeutics more than doubled last week after its drug candidate delivered solid clinical trial data. The company recently announced for its Harmoni-2 phase 3 trial, conducted in China in partnership with Akeso, where its lung cancer drug Ivonescimab showed a better progression-free survival period than Merck's Keytruda - the current standard for lung cancer treatment. That suggests Summit could gain significant traction in a market valued at $50 billion.
Citi identified Summit Therapeutics as a top pick after the clinical trial data for Ivonescimab, which drove the stock higher by nearly 56% in a single trading session last Monday. The data showed that the drug reduced the risk of disease progression or death by 49% compared to Keytruda.
Noting that Summit's candidate “unambiguously delivered" what Citi described as “unprecedented” results “against the gold-standard immunotherapy” in Keytruda, the brokerage firm raised its target price for SMMT stock to $19 from $13, stating it expects Ivonescimab to report peak risk-adjusted sales of $7.8 billion in the U.S. and Europe, above its earlier estimate of $5.3 billion.
Citi also expects increased retail attention as investors will “seek to own a name that has paradigm and practice-changing potential globally for the treatment of lung cancer and possibly other solid tumors.”
Summit Therapeutics Raises $235 Million
As Summit Therapeutics is still a pre-revenue company, it needs to raise capital to support its research and development expenses. Last week, Summit Therapeutics announced it accepted offers to raise $235 million from biotech institutional and individual investors.
Summit said that it intends to use the net proceeds to advance the clinical development of Ivonescimab, “including in non-small cell lung cancer and in settings outside of lung cancer by leveraging the data that will be presented at ESMO, which may include, but is not limited to, colorectal cancer, and triple-negative breast cancer, in addition to working capital needs and general corporate purposes.”
Is SMMT Stock a Good Buy Right Now?
Each of the three analysts covering SMMT stock has a “strong buy” recommendation. That said, the mean target price for Summit Therapeutics stock is $24.67, while the Street-high is $30 - both of which represent a discount to Friday's closing price of $31.93.
Ivonescimab may eventually become a blockbuster drug. However, it's difficult to estimate the impact of the lung cancer candidate on the company’s revenue and earnings, making SMMT stock a higher-risk investment right now.
On the date of publication, Aditya Raghunath did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
Sept 16 (Reuters) - Beyondspring Inc BYSI.O:
BEYONDSPRING PRESENTS EFFICACY/SAFETY RESULTS FROM A PHASE 2 STUDY OF PEMBROLIZUMAB PLUS PLINABULIN/DOCETAXEL IN METASTATIC NSCLC AFTER PROGRESSING ON FIRST-LINE IMMUNE CHECKPOINT INHIBITORS AT ESMO CONGRESS 2024
Source text for Eikon: (Full Story)
Further company coverage: BYSI.O
White Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.